Department of Hospital Medicine, University of Florida, Gainesville, FL, USA.
Department of Medicine, University of Florida, 1600 SW Archer Road, Room 4102, Gainesville, FL, 32610, USA.
J Med Case Rep. 2023 Mar 29;17(1):134. doi: 10.1186/s13256-023-03847-8.
RAD140 (Testalone) is a novel selective androgen receptor modulator with very limited data currently available on adverse effects related to this compound. The first-in-human phase 1 trial was recently published and did report a significant proportion of elevated aspartate aminotransferase, alanine transaminase, and total bilirubin among the test subjects. RAD140 may be associated with an idiosyncratic drug-induced liver injury. It is easily purchased online as a workout supplement. Given its ease of use from being an oral formulation, and not requiring a physician's prescription, its use among the young male population will likely rise. Clinicians should ask about the use of RAD140, and other workout supplements, in young men presenting with acute liver injury.
We present the case of a 26-year-old Caucasian male without any significant past medical history who presented with nausea, vomiting, severe right upper quadrant abdominal pain, and jaundice from acute liver injury. Extensive inpatient workup did not reveal a definite cause for his liver injury other than the use of a novel selective androgen receptor modulator called RAD140 (Testalone). He was treated with supportive care and discharged after short hospitalization. He was instructed to stop RAD140, which he reported compliance with, and on 2-month follow-up his liver function panel had normalized without recurrence of any symptoms.
Novel selective androgen receptor modulators such as RAD140 may be associated with idiosyncratic drug-induced liver injury. Workup of new liver injury in young and middle-aged males should involve asking about use of these novel compounds, for if missed and use continues, it can likely lead to fulminant liver failure or decompensated liver cirrhosis.
RAD140(Testalone)是一种新型选择性雄激素受体调节剂,目前关于该化合物相关不良反应的数据非常有限。最近发表了一项该化合物的人体首次 I 期临床试验,该试验确实报告了受试对象中相当一部分天门冬氨酸氨基转移酶、丙氨酸氨基转移酶和总胆红素升高。RAD140 可能与特发性药物性肝损伤有关。它作为一种运动补充剂很容易在网上购买。鉴于其作为口服制剂使用方便,且无需医生处方,因此在年轻男性中的使用可能会增加。临床医生应该询问年轻男性中 RAD140 和其他运动补充剂的使用情况,因为他们可能会出现急性肝损伤。
我们报告了一例 26 岁白人男性病例,无明显既往病史,因急性肝损伤出现恶心、呕吐、右上腹剧烈疼痛和黄疸。广泛的住院检查除了使用一种新型选择性雄激素受体调节剂 RAD140(Testalone)外,没有发现导致他肝损伤的明确原因。他接受了支持性治疗,并在短期住院后出院。他被指示停止使用 RAD140,据报告他已经遵守了医嘱,在 2 个月的随访中,他的肝功能指标已经正常,没有任何症状复发。
新型选择性雄激素受体调节剂,如 RAD140,可能与特发性药物性肝损伤有关。年轻和中年男性新发肝损伤的检查应包括询问这些新型化合物的使用情况,如果漏诊且继续使用,可能会导致暴发性肝衰竭或失代偿性肝硬化。